Full-Stack Agentic AI
for Molecular Binders
From target input to DNA/RNA binder in 24 hours.No SELEX. No wet lab. No guesswork.
Design your first binder01
Designed by AIDelivered in 24h
[The fastest binder design in the field]
Full-Stack
Agentic AI
End-to-end solution
Creating
a new category
Ready-to-use out of the box
P+L
Platform + Layer Infrastructure
24H
24-hour turnaround
$
Affordable pricing model
Problem
Drug discovery and diagnostics move fast. But binder development is stuck in the past: slow, expensive, and unreliable. XELARI changes that.
Solution
Our platform generates DNA and RNA binders – called XELAMERs – using proprietary agentic AI. You define the specs. We design the molecule.
Result
The result is a ready-to-test aptamer, engineered to your exact needs.
02
Unique featuresPlatform excellence
[The broadest range of capabilities]
Structure-Based Rational Design
The design utilizes all available information about the target structure
24h turnaround
Delivers structure, affinity data, and recommended modifications
Experimentally validated technology
Each technology is built on experimental data and confirmed by laboratory testing
Multiple Input Formats
Accession number, PDB structures, Binding site coordinates
Conversational AI Interface
Natural language assistance with structured field integration
Programmable Binding Parameters
Each binding parameter is tailored to perfectly match the request
03
Your ChoicesError-free generation
[All you need in one platform]
Natural
Backbone
Hydrophobic
Functional
Affinity
Specificity
Conditions
04
From input to binderin three clear steps
[The most accessible approach to modeling]
01
Step 1
[Upload your target]
02
Step 2
[Define your requirements]
03
Step 3
[Get your custom binders]
05
Platform WorkflowFrom Target to Binder
[MADE WITH AGENTIC AI]
incorporating specified features and chemical modifications
[Legend]
AI Orchestrator
Neural networks
Rule based algorithms
In-house closed
In-house open
06
XELAMERs
[Programmable DNA/RNA Tools]
Designed by proprietary agentic AI, XELAMERs are synthetic oligonucleotides that bind with precision to specific molecular targets, offering capabilities beyond traditional antibodies and aptamers
[XELAMER MODIFICATIONS] AVAILABLE THROUGH PLATFORM & API
07
Industry applications
[Applications across R&D verticals]
Biopharma
[biopharma benefits]
24-hour transition from target protein to in-silico validated aptamer with predefined affinity and stability.Parallel development of hundreds of candidates per quarter accelerates hit-to-lead, including for undruggable targets.
24-hour transition from target protein to in-silico validated aptamer with predefined affinity and stability.
[SEE MORE]
AI Drug Discovery
[AI Drug Discovery benefits]
Automated translation of AI-predicted targets into wet-lab-ready aptamers.Reduces AI → experimental cycle from months to days, enabling large-scale ML feedback and validation.
Automated translation of AI-predicted targets into wet-lab-ready aptamers.
[SEE MORE]
Multi-omics / Proteomics
[Multi-Omics / Proteomics benefits]
Custom binder design for novel protein targets without SELEX.Expands biomarker panels and reduces per-marker assay costs; supports hundreds of new reagents per quarter.
Custom binder design for novel protein targets without SELEX.
[SEE MORE]
CDMOs & QC
[CDMOs & QC benefits]
Aptamers for selective purification, impurity detection, and quality control.Deploys dozens of new QC methods per quarter with high reproducibility and integration into existing workflows.
Aptamers for selective purification, impurity detection, and quality control.
[SEE MORE]
Diagnostics
[Diagnostics benefits]
Stable, programmable aptamers for ELISA, LFA, and sensor platforms.Enhances assay sensitivity and thermal stability, speeding new diagnostic format launches.
Stable, programmable aptamers for ELISA, LFA, and sensor platforms.
[SEE MORE]
Aptamer CROs
[Diagnostics benefits]
In-silico lead generation with KD-based selection for SELEX and hybrid pipelines.Increases hit rate, reduces wet-lab cycles, and enables access to challenging targets.
In-silico lead generation with KD-based selection for SELEX and hybrid pipelines.
[SEE MORE]
Start designing now
Begin your first design todayNo SELEX. No wet lab. No guesswork.
Design your first binder